Roche shows Tecen­triq/Avastin com­bo helps liv­er can­cer pa­tients live longer

With an eye on a swelling Chi­nese mar­ket, Roche un­veiled Phase III da­ta show­ing a com­bi­na­tion of Tecen­triq, its im­munother­a­py, and Avastin could help pa­tients with the most com­mon form of liv­er can­cer live longer than un­der the stan­dard treat­ment, Bay­er’s Nex­avar.

In a tri­al of 501 un­re­sectable he­pa­to­cel­lu­lar car­ci­no­ma pa­tients, Roche’s cock­tail re­duced the risk of death by 42% and the risk of can­cer pro­gres­sion by 41% as com­pared to Nex­avar. Enough Tecen­triq pa­tients have lived long enough that Roche couldn’t yet de­ter­mine the me­di­an OS but those on Nex­avar passed away af­ter a me­di­an of 10.4 months.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.